Alligator Bioscience AB Employee Directory
Biotechnology ResearchLund, Sweden51-200 Employees
Alligator Bioscience AB is a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs. Alligator’s portfolio includes several promising drug candidates, with the CD40 agonist mitazalimab as its key asset. Furthermore, Alligator is co-developing ALG.APV-527 with Aptevo Therapeutics Inc., several undisclosed molecules based on its proprietary technology platform, Neo-X-Prime™, and novel drug candidates based on the RUBY™ bispecific platform with Orion Corporation. Out-licensed programs include AC101/HLX22, in Phase 2 development, by Shanghai Henlius Biotech Inc. and an undisclosed target to Biotheus Inc. Alligator´s technology platform comprises the proprietary technologies ALLIGATOR-GOLD® and FIND®. ALLIGATOR-GOLD® is a human antibody library containing more than 60 billion unique antibody fragments. FIND® (Fragment Induced Diversity) is a molecular evolution technology for optimization of antibodies and other proteins. Immunotherapy of cancer: The immune system protects the body from attacks by pathogenic microorganisms (e.g. viruses and bacteria) and by cancer cells. Cancer cells usually evade the immune system, for example by producing immunosuppressive substances. Thus, although tumors often contain a large number of immune cells that should be able to attack the cancer cells, they are unable to do so due to the immunosuppression caused by the tumor. With immunotherapy, the ability of the immune system to fight cancer cells is improved in an effective manner, and the defense mechanisms used by the tumor are blocked or weakened. In addition, immune cells capable of destroying the cancer cells will survive in the body and thus protect it from metastases that may arise after treatment has ended. This "vaccination effect" is unique for immunotherapy.
1-888-653-2347 
support@leadiq.com 
